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 ABSTRACT
Fabry’s disease is a recessive X -linked disorder that results from a deficiency of the hydrolase alpha-
-galactosidase A (α -Gal A). The absence of α -Gal A enzyme activity leads to accumulation of glycosphingolipid 
globotryaosylceramide (GL -3) in the lysosomes of a variety of cell types. It can cause skin and ocular lesions, 
progressive renal, cardiac or cerebrovascular disorders. The authors report the case of a 39 -year -old female 
who was referred to a nephrology appointment by her ophthalmologist, after the diagnosis of cornea ver-
ticillata and posterior subcapsular cataract. This case illustrates the importance of a multidisciplinary evalu-
ation to an effective clinical screening. In males, most symptoms begin in childhood; in females the onset 
can be observed later and presentation is more variable. Various manifestations often lead to misdiagnosis 
or are frequently delayed for many years. Enzyme replacement therapy highlights the importance of early 
diagnosis so that treatment can be initiated before irreversible organ damage occurs.
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 RESUMO
A Doença de Fabry é uma doença hereditária recessiva ligada ao X, que resulta da deficiência da enzima 
hidrolase α -galactosidade A (α -Gal A). A ausência de actividade da α -Gal A leva à acumulação de glicoes-
fingolípidos globotriaosilceramida (GL -3) nos lisossomas das células. É responsável por lesões cutâneas e 
oculares, bem como doença renal, cardíaca e cerebrovascular. Os autores apresentam uma doente de 39 
anos, género feminino que foi referenciada pelo seu Oftalmologista à consulta de Nefrologia, após o diag-
nóstico de córnea verticillata e catarata subcapsular posterior. Este caso ilustra a importância de uma equipa 
multidisciplinar na detecção da doença. No homem, a maioria dos sintomas inicia -se na infância; no género 
feminino, o início da sintomatologia ocorre mais tarde e a sua apresentação é mais variável. A heterogenei-
dade das manifestações leva ao erro ou atraso diagnóstico. O diagnóstico precoce é fundamental para que 
a terapêutica enzimática de substituição seja iniciada antes da lesão irreversível.
Palavras -Chave: Agalsidase beta; doença de Fabry; globotriaosilceramida; microalbuminúria.
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 CASE REPORT
The authors report a case of a 39 -year -old female 
who was referred to a nephrology appointment by 
her ophthalmologist, after the diagnosis of cornea 
verticillata and posterior subcapsular catarat. She 
presented with progressive decrease of visual acuity, 
chronic fatigue, and mild periorbital oedema. She 
denied other symptoms like dermatologic, neurologic 
or cardiac ones. Her past medical history was unre-
markable, however, her maternal grandmother died 
with end -stage renal disease (ESRD) on regular hae-
modialysis programme (no cause was identified at 
that time). Chronic medication: Ginera ® id. She had 
normal blood pressure, normal cardiopulmonary aus-
cultation, normal urine output and mild malleolar 
and periorbital oedema. The review of systems was 
otherwise negative. Blood laboratory investigation 
showed mild mixed dyslipidaemia, normal renal func-
tion, as well as normal’s blood count. Urinalysis 
showed 9 leucocyte/hpf and 11 erythrocyte/hpf, glo-
merular hyperfiltration (140 ml/min/1.73 m2) and 
proteinuria (1254 mg/24h). Eletrocardiogram, chest 
X -ray, abdominal ultrasound and echocardiogram 
were normal. Renal ultrasound presented normal 
morphology and dimensions of both kidneys, with 
milimetric parapielic cysts. Brain magnetic resonance 
imaging (MRI) revealed images of small dimensions 
related to outbreaks of gliosis resulting from small 
vascular sequelae. Urinary GL3 excretion was 
increased. Biochemistry analysis confirmed low leu-
cocytes α-Gal A activity. Molecular study identified 
the mutation c.317_27del11(pL106fs).
Genetic study of her family found both parents 
being negative. Concerning her descendants, she 
has one 5 -year -old girl and one 8 -year -old boy that 
were positive and negative for the mutation, respec-
tively. They are being followed in a genetic paediatric 
consultation.
After the diagnosis confirmation, she was started 
on enzyme replacement therapy (agalsidase beta 1 
mg/kg every 15 days). Adjuvant therapy was started 
with an aldosteron receptor blocker (Losartan 50 mg 
id) and colecalcipherol (15000 UI/week).
The patient has been under therapy for one year, 
and is asymptomatic, with normal renal function 
(serum urea 4 mg/dL, creatinine 0.71 mg/dL, eGFR 
155 ml/min), and a proteinuria of 1.4 grs/day.
 REVIEW
Fabry’s disease (FD) is a rare, inherited, recessive 
X -linked disorder caused by mutations in the gene 
encoding the acid hydrolase enzyme alpha-
-galactosidase A (EC 3.2.1.22), which causes defi-
ciency of the lysosomal hydrolase alpha -galactosidase 
A (α-Gal A)1. More than 700 types of mutations have 
been identified, but they are usually family specific. 
Most of the described mutations are associated with 
the classic Fabry’s phenotype, in which there is mul-
tisystem involvement2. The genetic study of our 
patient’s family was made and her parents were both 
negative, meaning that she has a de novo mutation. 
Some authors have found some correlation between 
specific mutational and enzyme activity levels and 
have proposed that a classification related to this 
association will facilitate the diagnosis of Fabry’s 
disease3.
The incidence of FD hemizygosity is generally esti-
mated as 1 in 40,000 to 50,000 males4,5; however, 
recognition of atypical forms of the disease and 
neonatal screening6 suggest that the actual figure 
may be much higher.
Regarding pathophysiology, the absence or deficient 
of α -Gal A enzyme activity leads to accumulation of 
glycosphingolipid globotryaosylceramide (GL -3) in the 
lysosomes of a variety of cell types including capillary 
endothelial, renal (podocytes, tubular cells, glomerular 
endothelial, mesangial and interstitial cells), cardiac 
(cardiomyocytes and fibroblasts) and nerve cells5 caus-
ing cellular dysfunction and microvascular pathology. 
The lysosomal storage starts before birth and is the 
only feature during the first stage of the disease (pri-
mary disease). After some years, the disease progresses 
to cellular dysfunction, which defines the second stage 
(secondary disease). It is characterized by compromised 
energy metabolism7 -9, small vessel injury10, K/Ca 3.1 
channel dysfunction in endothelial cells11, oxidative 
stress12, impaired autophagosome maturation13 and 
tissue ischaemia. The last and worse stage of FD is 
caused by cellular death with the development of 
irreversible cardiac14 -16 and renal17 tissue fibrosis (ter-
tiary disease). These three stages of the disease reflect 
a heterogeneous, progressive clinical picture. In the 
primary stage, patients have no symptoms and the 
only evidence of disease is through a tissue biopsy 
where is seen a lysosomal accumulation of Gb3 and 
related glycosphingolipids. The secondary stage is 
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characterized by mild symptoms and the evidence of 
the disease is often found through complementary 
exams that translate cellular dysfunction of the affected 
organs. The tertiary stage reflects the target organs 
failure with end -stage renal disease, heart failure or 
acute myocardial infarction and stroke, which are 
irreversible18 -20.
During the natural course of the disease, several 
symptoms may begin according to the target organs 
affected that may vary among patients, contributing 
to the called “classical or atypical variants” according 
to the dominant manifestations. In classically affected 
male patients, clinical onset occurs in childhood; 
however, this may not be true for females because 
the X inactivation is incomplete and the enzyme 
activity level can be from zero to almost normal21.
Early neuronal damage of small nerve fibres of the 
peripheral somatic22 and autonomic nerve systems23
correlates with the onset of episodic abdominal pain 
crises (“Fabry crises”), as well as, chronic pain, hypo-
hidrosis/anhidrosis and paresthesias24. Cerebrovas-
cular disease evidence starts with asymptomatic white 
matter lesions in the magnetic resonance imaging 
(MRI), but symptoms like dizziness, transient ischae-
mic attacks, and stroke are representative.
Skin lesions, mainly angiokeratomas, can be found 
in several forms, locations and sizes, which usually 
increase with age25.
Regarding eye disease, the most specific, almost 
pathognomonic and common finding is cornea ver-
ticillata (corneal deposits) but other abnormalities 
can occur, like vascular tortuosities and posterior 
subcapsular cataract26. The main differential diag-
nosis causing cornea verticillata is a side -effect of 
chronic amiodarone that was excluded.
Heart and kidney are the two remaining affected 
organs that most compromise life expectancy. Cardiac 
disease starts with concentric hypertrophy and 
remodelling of myocardium, which leads to irrevers-
ible endocardic fibrosis, conduction abnormalities, 
valvulopathy and myocardial infarction2. The best 
complementary diagnostic exam to evaluate cardiac 
involvement is cardiac MRI, which highlights fibrosis. 
However it is worth to mention that electrocardiogram 
often shows a shortened PR interval when there is 
a conduction compromise2.
Sphingolipids play an important role in modulating 
podocyte function, so nephropathy is one of the 
major complications of FD. Approximately 30–35% 
of females have proteinuria5,27, 13% have stage 3 
CKD28 and 1–4% have ESRD29. The decline in renal 
function over time is related to the degree of pro-
teinuria and, in untreated patients, is more rapid 
when the eGFR is below 60 ml/min/1.73 m2. Before 
renal replacement therapies were available, the mor-
tality rate was 100% between the ages of fifties and 
sixties30. Nowadays, the prevalence of patients with 
ESRD due to FD starting dialysis probably underes-
timates the reality because not all patients undergo 
a renal biopsy. Additionally, the prevalence among 
young males who initiate dialysis before the age of 
40 years, for example, may be higher. According to 
both American and European databases, FD patients 
that initiate dialysis have a worse survival compared 
with non -Fabry controls31. Although these patients 
have a higher cardiovascular risk due to cardiac 
increased adiposity, hypertension, dyslipidaemia and 
immunosuppression side -effects, when they undergo 
renal transplantation, their overall and graft survival 
is comparable to matched controls31.
One of the earlier signs of nephropathy is micro-
albuminuria. Over time, the proteinuria under the 
nephrotic range is the most typical form of presenta-
tion and is an independent risk factor affecting the 
extent of renal decline, as well as determining the 
success of ERT32,33. A proteinuria level above 1 g/d 
is associated with a worst prognosis18,34. Other fea-
tures are glomerular hyperfiltration; impaired con-
centration ability due to distal tubular involvement; 
and increased urinary Gb3 excretion35. Urinalysis 
may be quite variable and microscopy may be useful 
in the diagnosis because vacuolated epithelial cells 
filled with glycosphingolipids give the appearance 
of a ‘Maltese cross’ when polarized light microscopy 
is used36, and they are very specific. Although patho-
genesis is not known, renal ultrasound presents 
parapielic cysts in up to 50% of patients37. A wide 
range of renal histopathology could be found due 
to diffuse deposition of glycosphingolipid in the glo-
meruli, tubules, and vasculature. Light microscopic 
findings include a “foamy” appearance of the glo-
meruli with diffuse swelling and vacuolization of 
visceral podocytes38; mesangial expansion and pro-
gressive segmental and global glomerulosclerosis39 -41. 
Electron microscopy shows podocytes and mesangial 
cells filled with lysosomal electron dense granules 
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arranged in a lamellar, myelin pattern38. One study 
found that podocyte Gb3 inclusion volume and den-
sity, as well as foot process width were shown to 
increase with age and to be directly correlated with 
proteinuria42. Although not yet confirmed, this evi-
dence illustrates that a podocytopathy plays a key 
role in FD.
As seen with other nephropathies, glomerular 
sclerosis and tubulo -interstitial fibrosis, although not 
specific, are the histological features that best cor-
relate with the progression of renal disease43. A 
glomerular sclerosis above 50% predicts a worst 
prognosis44.
Concerning diagnosis of FD, enzymatic analyses 
of dried blood spots allow population screening and 
an initial diagnosis in males45, while in heterozygous 
females, in whom alpha -galactosidase A activity is 
highly variable, genotyping is essential for a diagno-
sis. Adding to this, a target organ biopsy that reveals 
deposition of the glycosphingolipid can also confirm 
the diagnosis. Although not vital for diagnosis, kidney 
biopsy may have an important role to assess and 
monitor disease progression46. It should also be 
undertaken if there is the possibility of double pathol-
ogy (e.g., diabetes or other glomerular diseases), 
especially if the patient is hypertensive; or there is 
a sudden, unexplained decline in renal function47.
With age, progressive damage to vital organ systems 
develops and life -threatening renal, cardiovascular or 
cerebrovascular complications limit life -expectancy of 
untreated males and females to approximately 50 and 
70 years, respectively2.
Management of FD relies on enzyme replacement 
therapy (ERT)48,49, but adjuvant therapies50,51 are also 
important. It has been shown to improve the clinical 
outcome of patients with FD, including stabilization 
of kidney function52 -54. However, because clinical trials 
are difficult to carry out in rare disorders, such as FD, 
adding to the heterogeneous presentation, no evi-
dence is available to support the optimal timing to 
initiate it or to identify which patients are most likely 
to gain significant benefit from therapy55. The ERT 
appears not to have beneficial effect on overt pro-
teinuria in adults56,57, especially in men, but stabiliza-
tion of renal function may be seen with ERT if pro-
teinuria can be controlled using renin -angiotensin 
system blockers58. No biomarker or monitoring 
strategy has been identified until now. The ERT is 
currently available with recombinant A -galactosidase, 
including agalsidase -α (Replagal; Shire Pharmaceuti-
cals) and agalsidase -β (Fabrazyme; Genzyme Corpora-
tion), the second one being the only approved by the 
Food and Drug Administration (FDA) and the European 
Medicines Agency (EMA) for specific treatment of 
FD52,59. Recent data46 described a reduction, and 
even clearing, of podocyte GL -3 deposits that was 
related to the cumulative dose of ERT received, and 
the reductions in urinary albumin excretion paralleled 
the reductions in podocyte GL -3 deposits.
 CONCLUSIONS
This case illustrates the importance of a multidis-
ciplinary evaluation to an effective clinical screening. 
It should be noticed once more that a negative family 
history does not exclude the diagnosis because a 
de novo mutation can happen at any time.
Although most women are heterozygous and remain 
asymptomatic60, this case confirms that women should 
not be considered silent carriers of the mutation and 
they are potential victims for severe organ damage 
and death due to heart and kidney involvement.
At the present time, available evidence emphasizes 
the importance of the podocyte in relation to pro-
teinuria, an important indicator of disease progres-
sion61. In this setting, this disease should not be 
forgotten in the differential diagnosis of proteinuria 
(especially under the nephrotic range) of uncertain 
origin, mainly based on the importance of starting 
ERT early, before there is major irreversible organ 
damage. We are hopeful that additional biomarkers 
will be validated in the future and will assist in the 
treatment decisions and patient monitoring.
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